Pipeline

ABL501

HomePipelineABL501

  • Pipeline
    ABL501
  • Program Target
    PD-L1 x LAG-3
  • Disease Indication
    Solid Tumor
  • Development Stage
    Early Development
Summary
ABL501 is a bispecific antibody combining PD-L1 and LAG-3 checkpoint pathways to overcome the current limitation of PD-(L)1 therapy by blocking two immune suppressors. ABL501 is a full length anti-LAG-3 mAb fused with scFv of PD-L1 engaging mAb. ABL501 shows better activity over combination or bispecific antibody of anti-PD-1 and anti-LAG-3 from competitors. ABL501 shows superior activity than monotherapy and combination.

Structure and Mechanism of Action

Structure and Mechanism of Action
좌우스크롤 Structure and Mechanism of Action

Superior Activity than Mono and Combination

Superior Activity than Mono and Combination
Superior Activity than Mono and Combination

Superior Activity over Competitors

Superior Activity over Competitors
Superior Activity over Competitors